Please assess the completion status of the following clinical trial:

Trial Title: Celecoxib in Treating Patients With Early-Stage Rectal Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Clinical diagnosis of primary adenocarcinoma of the rectum (to be histologically confirmed upon study entry)~  * Tumor must be at or below the peritoneal reflection~ * The distal border of the tumor is within 12 cm of the anal verge on proctoscopic examination~* Clinically resectable disease~PATIENT CHARACTERISTICS:~* Karnofsky performance status 60-100%~* WBC ≥ 4,000/mm³~* Platelet count ≥ 150,000/mm³~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception~* No other serious medical illness (other than rectal cancer) that would preclude study therapy~* No psychiatric condition that would preclude informed consent~* No history of allergy to celecoxib or any other NSAIDs, including acetylsalicylic acid (i.e., aspirin), ibuprofen, or indomethacin~* No history of allergy to sulfonamides~Exclusion criteria:~Not noted~PRIOR CONCURRENT THERAPY:~* At least 7 days since prior and no concurrent NSAIDs or other cyclooxygenase-2 inhibitors~* No concurrent warfarin, except low-dose warfarin (i.e., 1 mg/day) administered for prophylaxis

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Therapeutic Intervention/Celecoxib (Type: EXPERIMENTAL): Celecoxib

Based on this trial design, predict the completion outcome and termination type (if applicable).